Biofeedback therapy combined with Baduanjin on quality of life and gastrointestinal hormone level in patients with colorectal cancer

doi:10.4251/wjgo.v14.i6.1187

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 14, Issue 6

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (3084)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-6) series.

Item

Count

PDF

151

WORD

HTML

1222

Tables (1-6)

157

Sum=1602

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

175

Download

486

Sum=661

Publishing Process of This Article

Item

Count

Browse

256

Download

559

Sum=815

Jun 15, 2022 (publication date) through Jul 27, 2024

Times Cited of This Article

Times Cited (4)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Randomized Controlled Trial

World J Gastrointest Oncol. Jun 15, 2022; 14(6): 1187-1198
Published online Jun 15, 2022. doi: 10.4251/wjgo.v14.i6.1187

Table 1 General data of four groups of patients (n = 112, mean ± SD)

	Group A	Group B	Group C	Group D	Statistic	P value
Number of cases (Male/female)	15/14	16/12	15/13	15/12	0.19	0.98
Age (yr)	52.89 ± 6.43	53.93 ± 7.63	52.79 ± 5.85	54.70 ± 6.29	0.53	0.66
BMI	21.17 ± 1.35	21.49 ± 1.02	21.55 ± 1.14	20.95 ± 1.32	1.49	0.22
Operation site/case					0.93	0.99
Left colon	8	8	6	8
Right colon	6	7	8	6
Rectum	15	13	14	13

BMI: Body mass index.

Table 2 Clinical efficacy of four groups

Group	Number of cases	Show effect	Alleviate	Effective	Be invalid	Total effective rate
Group A	29	1	6	8	14	51.72%^b
Group B	28	3	8	8	9	67.86%^a
Group C	28	3	11	6	8	71.43%
Group D	27	7	14	4	2	92.59%

^aP < 0.05, between group D, group A, group B and group C 12 wk after intervention.

^bP < 0.01, between group D, group A, group B and group C 12 wk after intervention.

Table 3 Symptom scoring scale of constipation (mean ± SD, score)

Group	Baseline	12 wk
Group A	16.52 ± 0.91	16.14 ± 0.99
Group B	16.36 ± 1.03	12.25 ± 1.93^b^,^d
Group C	16.39 ± 0.96	12.11 ± 1.93^b^,^d
Group D	16.22 ± 1.12	9.52 ± 1.72^b^,^d

^bP < 0.01, the intra-group comparison of each group at different time points.

^dP < 0.01, the comparison of group B, group C and group D with the group A at the same time point.

Table 4 QLQ-CR38 scores of four groups before and after treatment (mean ± SD, min)

Group dimension	Group A		Group B		Group C		Group D
Group dimension	Baseline	12 wk	Baseline	12 wk	Baseline	12 wk	Baseline	12 wk
Functional dimension
Body image	43.17 ± 16.45	49.45 ± 12.25^a	41.32 ± 16.77	50.46 ± 13.24^b	43.43 ± 17.16	53.43 ± 15.05^b	42.48 ± 13.38	79.78 ± 13.75^b^,^e
Future expectation	42.48 ± 13.27	47.48 ± 11.83	42.14 ± 14.42	61.93 ± 15.58^b^,^e	43.64 ± 16.65	62.75 ± 15.16^b^,^e	41.52 ± 15.60	80.48 ± 10.68^b^,^e
Sexual function	23.45 ± 9.49	30.45 ± 12.65^b	24.32 ± 8.35	35.82 ± 12.42^b	22.64 ± 8.13	36.46 ± 11.55^b	23.48 ± 9.37	43.33 ± 13.38^b^,^e
Sexual satisfaction	38.52 ± 12.42	43.30 ± 13.72^a	39.07 ± 11.26	52.29 ± 11.92^b^,^e	40.07 ± 14.27	53.71 ± 12.60^b^,^e	39.33 ± 13.21	65.07 ± 14.07^b^,^e
Symptom dimension
Urination problem	45.28 ± 14.14	42.38 ± 12.05	44.86 ± 13.64	35.29 ± 10.73^b^,^d	46.18 ± 12.16	35.29 ± 12.39^b^,^d	44.56 ± 13.60	23.44 ± 7.80^b^,^e
Gastrointestinal symptoms	37.34 ± 13.55	35.45 ± 11.06	38.46 ± 16.65	28.50 ± 12.71^b^,^d	37.21 ± 15.35	27.54 ± 10.85^b^,^e	38.44 ± 14.19	17.63 ± 9.37^b^,^e
Adverse reactions of chemotherapy	14.34 ± 4.53	29.28 ± 6.64^b	15.54 ± 7.09	26.18 ± 7.49^b	15.46 ± 5.90	25.96 ± 5.98^b	15.26 ± 5.16	18.41 ± 4.91^a^,^e
Defecation problem	23.52 ± 9.70	35.38 ± 8.67^b	24.18 ± 8.64	30.18 ± 7.83^b^,^d	23.43 ± 7.36	29.82 ± 9.29^b^,^d	24.56 ± 8.16	26.33 ± 6.52^e
Issue related to stoma	50.45 ± 11.30	44.52 ± 11.23^a	50.50 ± 10.90	36.29 ± 9.08^b^,^e	49.54 ± 12.23	38.18 ± 6.91^b^,^e	49.33 ± 11.68	24.74 ± 6.76^b^,^e
Male sexual problems	60.83 ± 14.90	51.07 ± 13.44^b	62.11 ± 11.25	45.71 ± 12.18^b	60.93 ± 14.03	43.64 ± 10.73^b^,^d	61.56 ± 13.27	42.63 ± 11.08^b^,^e
Female sexual problems	26.72 ± 8.69	23.38 ± 5.80^b	27.43 ± 7.71	21.68 ± 5.83^b	27.86 ± 6.90	20.36 ± 5.70^b	27.52 ± 8.10	18.30 ± 5.77^b^,^e
Body mass	54.48 ± 14.19	49.41 ± 11.97^a	55.32 ± 13.65	41.11 ± 9.87^b^,^e	55.18 ± 11.44	42.68 ± 11.67^b^,^d	55.11 ± 16.54	34.74 ± 9.65^b^,^e

^aP < 0.05, the intra-group comparison of each group at different time points.

^bP < 0.01, the intra-group comparison of each group at different time points.

^dP < 0.05, the comparison of group B, group C and group D with the group A at the same time point.

^eP < 0.01, the comparison of group B, group C and group D with the group A at the same time point.

Table 5 Gastrointestinal hormone levels in peripheral blood of four groups (mean ± SD, pg·mL^-1)

Group	MTL		SS
Group	Baseline	12 wk	Baseline	12 wk
Group A	146.07 ± 28.42	159.28 ± 25.69	120.17 ± 21.84	124.52 ± 23.38
Group B	151.75 ± 25.54	192.79 ± 22.75^b^,^d	131.18 ± 22.11	110.36 ± 22.49^b^,^d
Group C	147.57 ± 20.43	189.46 ± 25.06^b^,^d	125.36 ± 19.81	114.14 ± 21.10^b^,^d
Group D	144.52 ± 22.41	269.33 ± 24.74^b^,^d	119.52 ± 21.12	70.26 ± 20.53^b^,^d

^bP < 0.01, the intra-group comparison of each group at different time points.

^dP < 0.01, the comparison between group d, group a, group b and group c at the same time point.

MTL: Levels of motilin; SS: Levels of somatostatin.

Table 6 Correlation between gastrointestinal hormone levels and scores of functional areas of quality of life in colorectal cancer patients (R)

Project	Constipation symptom score	MTL	SS
Body image	-0.376^b	0.617^b	-0.532^b
Future expectation	-0.530^b	0.569^b	-0.446^b
sexual function	-0.334^b	0.290^b	-0.243^b
Sexual satisfaction	-0.375^b	0.369^b	-0.250^b
Urination problem	0.393^b	-0.448^b	0.334^b
Gastrointestinal symptoms	0.436^b	-0.390^b	0.238^a
Adverse reactions of chemotherapy	0.329^b	-0.431^b	0.305^b
Defecation problem	0.265^b	-0.002	0.166
Issue related to stoma	0.507^b	-0.528^b	0.410^b
Male sexual problems	0.151	-0.643^b	0.803^b
Female sexual problems	0.305^b	-0.244^b	0.190^a
Body mass	0.314^b	-0.284^b	0.195^a

^aP < 0.05, between gastrointestinal hormone levels and scores of functional areas of quality of life in colorectal cancer patients.

^bP < 0.01, between gastrointestinal hormone levels and scores of functional areas of quality of life in colorectal cancer patients.

MTL: Levels of motilin; SS: Levels of somatostatin.

Citation: Zhou XD, Wei HG, Ai FL. Biofeedback therapy combined with Baduanjin on quality of life and gastrointestinal hormone level in patients with colorectal cancer. World J Gastrointest Oncol 2022; 14(6): 1187-1198
URL: https://www.wjgnet.com/1948-5204/full/v14/i6/1187.htm
DOI: https://dx.doi.org/10.4251/wjgo.v14.i6.1187